Table Info

Table 1.

The medications administered to the patient throughout his admission

Medication	Dose	Frequency
Meropenem	1 g	Q8h (every 8 hours)
Levofloxacin	500 mg	Q24h (every 24 hours)
Hydrocortisone	100 mg	Q8h (every 8 hours)
Tramadol	100 mg	PRN (given twice)
Paracetamol	1 g	Q8h (every 8 hours)
Gentamicin eye drops	N/A	Q12h (every 12 hours)
IV pantoprazole	40 mg	Q24h (every 24 hours)
IV metoclopramide	10 mg	N/A
Amikacin infusion	500 mg	Q12h (every 12 hours)
IV tranexamic acid	500 mg	N/A
Salbutamol	N/A	N/A
Ipratropium	N/A	N/A
Filgrastim syringe	300 mcg	N/A
IV furosemide	40 mg	Q12h (every 12 hours)
Fluconazole infusion	100 mg	Q12h (every 12 hours)
IV N-acetyl cysteine	400 mg	Q8h (every 8 hours)

IV: intravenous

Declarations

Author contributions

AA, HAD, and DM: Conceptualization, Data curation, Resources, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. MAK, EAN, BK, and DB: Data curation, Resources, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. AE: Conceptualization, Data curation, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

This observational study on a human subject was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and received ethical approval from the Research Ethical Committee (REC) of the Faculty of Medicine and Health Sciences, University of Science and Technology, Sana’a, Yemen (Approval No. UST-IRB-2024-014). The authors are accountable for all aspects of the work, ensuring that any questions regarding the accuracy or integrity of the study are appropriately investigated and resolved.

Consent to participate

Informed consent to participate in the study was obtained from the patient.

Consent to publication

Written informed consent was obtained from the patient to publish this case report and any accompanying images. A copy of the written consent is available for review by the journal’s Editor-in-Chief.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on a reasonable request.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Justiz Vaillant AA, Modi P, Mohammadi O. Graft-Versus-Host Disease. Treasure Island (FL): StatPearls Publishing; 2025. [PubMed]

Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021;39:19–49. [DOI] [PubMed] [PMC]

Sousa PSE, Bennett CL, Chakraverty R. Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease. Front Immunol. 2018;9:963. [DOI] [PubMed] [PMC]

Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667–74. [DOI] [PubMed]

Manduzio P. Transfusion-associated graft-versus-host disease: A concise review. Hematol Rep. 2018;10:7724. [DOI] [PubMed] [PMC]

Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377:2167–79. [DOI] [PubMed] [PMC]

Hutchinson K, Kopko PM, Muto KN, Tuscano J, O’Donnell RT, Holland PV, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002;42:1567–72. [DOI] [PubMed]

Rutter S, Tormey CA, Gokhale A. Noninfectious Complications of Transfusion: Adverse Events. In: Clinical Principles of Transfusion Medicine. Elsevier; 2018. pp. 69–84.

Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang. 2008;95:85–93. [DOI] [PubMed]

10.

Fast L. Preventing transfusion-associated graft-versus-host disease: state of the art. Int J Clin Transfus Med. 2015;2015:1–6. [DOI]

11.

Malladi SVS, Paul R, Chandra N, Rao NM, Raju SY. TA-GVHD, a Fatal Complication Following Blood Transfusion from a First-Degree Relative. J Obstet Gynaecol India. 2013;63:344–6. [DOI] [PubMed] [PMC]

12.

Kopolovic I, Ostro J, Tsubota H, Lin Y, Cserti-Gazdewich CM, Messner HA, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood. 2015;126:406–14. [DOI] [PubMed]

13.

Akay MO, Temiz G, Teke HU, Gunduz E, Acikalin MF, Isiksoy S, et al. Rapid molecular cytogenetic diagnosis of transfusion associated graft-versus-host disease by fluorescent in situ hybridization (FISH). Transfus Apher Sci. 2008;38:189–92. [DOI] [PubMed]

14.

Budhai A, Francis RO, Shaz BH. Transfusion-Associated Graft-versus-Host Disease and Microchimerism. In: Murphy MF, Roberts DJ, Yazer MH, Dunbar NM, editors. Practical Transfusion Medicine. Practical Transfusion Medicine. John Wiley & Sons, Ltd; 2022. pp. 166–80. [DOI]

15.

Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al.; United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. Br J Haematol. 2015;168:26–37. [DOI] [PubMed]

16.

Elmakki EE, Madkhali MA, Oraibi O, Alqassimi S, Saleh E. Transfusion-Associated Graft-Versus-Host Disease in Adults. Cureus. 2023;15:e44148. [DOI] [PubMed] [PMC]

17.

Foukaneli T, Kerr P, Bolton-Maggs PHB, Cardigan R, Coles A, Gennery A, et al.; BCSH Committee. Guidelines on the use of irradiated blood components. Br J Haematol. 2020;191:704–24. [DOI] [PubMed]

18.

Loingsigh SN, Flegel WA, Hendrickson JE, Tormey CA. Preventing transfusion-associated graft-versus-host disease with blood component irradiation: indispensable guidance for a deadly disorder. Br J Haematol. 2020;191:653–7. [DOI] [PubMed] [PMC]

19.

Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016;7:S21–31. [DOI] [PubMed] [PMC]

20.

Shapiro RM, Antin JH. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020;13:519–32. [DOI] [PubMed]

21.

Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792–800. [DOI] [PubMed]

22.

Kumar G, Ahmad S, Taneja A, Patel J, Guddati AK, Nanchal R, et al.; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators. Severe sepsis in hematopoietic stem cell transplant recipients. Crit Care Med. 2015;43:411–21. [DOI] [PubMed]

23.

Elliot J, Narayan S, Poles D, Tuckley V, Bolton-Maggs PHB. Missed irradiation of cellular blood components for vulnerable patients: Insights from 10 years of SHOT data. Transfusion. 2021;61:385–92. [DOI] [PubMed] [PMC]